

University of Groningen

Scaffolding-Induced Property Modulation of Chemical Space

Li, Jingyao; Di Lorenzo, Vincenzo; Patil, Pravin; Ruiz-Moreno, Angel J.; Kurpiewska, Katarzyna; Kalinowska-Tłuścik, Justyna; Velasco-Velázquez, Marco A.; Dömling, Alexander

Published in:
Acs combinatorial science

DOI:
[10.1021/acscombsci.0c00072](https://doi.org/10.1021/acscombsci.0c00072)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Li, J., Di Lorenzo, V., Patil, P., Ruiz-Moreno, A. J., Kurpiewska, K., Kalinowska-Tłuścik, J., Velasco-Velázquez, M. A., & Dömling, A. (2020). Scaffolding-Induced Property Modulation of Chemical Space. *Acs combinatorial science*, 22(7), 356-360. <https://doi.org/10.1021/acscombsci.0c00072>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Scaffolding-Induced Property Modulation of Chemical Space

Jingyao Li, Vincenzo Di Lorenzo, Pravin Patil, Angel J. Ruiz-Moreno, Katarzyna Kurpiewska, Justyna Kalinowska-Źłusciak, Marco A. Velasco-Velázquez, and Alexander Dömling*



Cite This: *ACS Comb. Sci.* 2020, 22, 356–360



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Physicochemical property switching of chemical space is of great importance for optimization of compounds, for example, for biological activity. Cyclization is a key method to control 3D and other properties. A two-step approach, which involves a multicomponent reaction followed by cyclization, is reported to achieve the transition from basic moieties to charge neutral cyclic derivatives. A series of multisubstituted oxazolidinones, oxazinanones, and oxazepanones as well as their thio and sulfur derivatives are synthesized from readily available building blocks with mild conditions and high yields. Like a few other methods, MCR and cyclization allow for the collective transformation of a large chemical space into a related one with different properties.

KEYWORDS: multicomponent reaction, cyclic carbamate, Ugi reaction, cyclization, tetrazole, scaffold diversity




INTRODUCTION


The property design of organic compounds is of uttermost importance during the process of optimization to obtain compounds with perfect performance. Properties such as charges or neutrality and 3D distribution of lipophilic or hydrogen donor/acceptor moieties are introduced into molecules by an often lengthy, stepwise, and sequential pathway. The principles of multicomponent reaction chemistry (MCR) allow for an orthogonally different approach.¹ In an intellectually and operationally easy building block approach, complex molecules are assembled in one step from a very large number of available building blocks.^{2–5} Among, the most commonly used derivatizations are cyclizations, which often change the properties dramatically. In the context of medicinal chemistry, cyclizations are often introduced to rigidify and generate a conformation similar to the receptor-bound structure and also to modify druglike properties such as stability to metabolism or increasing permeability.⁶ By overlapping the 3D structure of cyclic and noncyclic compounds, stabilization via cyclization and a shift of the terminal moiety were observed (Figure 1A). While the number of primary MCRs with useful synthetic properties such as great scope, ease of performance and large number of building blocks (and thus chemical space) is limited, the number of secondary transformations and especially cyclizations is infinite. Hulme and others introduced the very useful concept of UDC (Ugi-deprotection-cyclization) resulting in Epelsiban and Retosiban, which are currently being tested in advanced clinical trials.^{7,8}

Carbamate containing heterocycles are abundantly present as dominant moieties in a number of valuable chemicals and therapeutic agents in modern drug discovery and material science development.⁹ Cyclic carbamate moieties not only are


A: 3D structure comparison of cyclic and noncyclic compounds



B: Representative Drugs containing a cyclic carbamate moiety



C: Previous synthetic approaches to cyclic carbamates



D: MCR/cyclization sequence (our work)





Figure 1. Cyclization strategies in chemistry.

Received: April 30, 2020

Revised: May 22, 2020

Published: May 22, 2020



present in many drugs (Figure 1B) but also play important roles in several chemical processes such as chiral auxiliaries^{10,11} and in the preparation of hyperbranched polymers.^{12,13} In particular, 6-membered (2-oxazinanone) cyclic carbamates have cumulatively been regarded as privileged scaffolds in drug discovery due to excellent chemical stability and cell membrane permeability. Owing to the prominent medicinal and industrial applicability of cyclic carbamates, various synthetic routes have been exploited (Figure 1C).¹⁴ The classical approaches generally involve either phosgene and its derivatives,^{15,16} alkyl halide chemistry,¹⁷ or sacrificial reagents,¹⁸ such as urea and organic carbonates. Shortly afterward, several other synthetic approaches have been developed to supersede these dissipative, costly, and environmentally hazardous methods. Nevertheless, the following reactions confront various defects, for instance, harsh reaction conditions (0 °C or heating),¹⁹ catalyst requirement,²⁰ difficult to access starting materials,^{21,22} long reaction time,²³ multiple steps,²⁴ low yields,²⁵ and limited scope.²⁶

Our strategy for a cyclization-induced property change based on MCR chemistry was to use bifunctional orthogonal amino and hydroxyl aldehydes in specific variants of the Ugi reaction, GBB-3CR and UT-4CR, followed by a secondary cyclization on the intermediates to yield (thio) carbamates, ureas, and amino sulfonic acid esters of 6- and 7-membered ring size (Figure 1D).

RESULTS AND DISCUSSION

The azido-Ugi product **1a**, which features a secondary amine, was chosen as the model substrate to verify this hypothesis. Salicylaldehyde was selected in this azido-Ugi reaction as the supplier of the free hydroxyl group. 1,1'-Carbonyldiimidazole (CDI) is a coupling reagent mainly used for the synthesis of amides, peptides, and carbamates as well as ureas.^{27,28} Therefore, we envisioned that CDI could enable the desired cyclic carbamate formation by affording the carbonyl group to the MCR product. Having synthesized the corresponding Ugi-tetrazole in hand, the optimization started with 1 equiv of CDI in DCM at room temperature, giving a moderate yield of 76% (Table 1, entry 1) after 3 h. Further optimization was conducted by increasing either temperature or the equivalent of CDI. As expected, both conditions performed better yields

of 83% (Table 1, entry 2) and 93% (Table 1, entry 3), respectively. Several studies indicated that a catalytic amount of base in the CDI reaction will accelerate the formation of the corresponding product.²⁹ However, subsequent attempts have shown that the utilization of base (Table 1, entries 5 and 6) restricts the reaction process, even with a longer reaction time. To our delight, superior conditions were found with a shorter reaction time without heating. In the optimal protocol, 1.5 equiv of CDI was added to a solution of the azido-Ugi product in DCM at room temperature under air, and the corresponding oxazinanone was formed with nearly quantitative yield in a few hours (Table 1, entry 9).

Under optimized conditions, we next examined the substrate scope of cyclization with various amines, isocyanides, and salicylaldehydes with diverse substitutions (Scheme 1). The majority of the corresponding oxazinanones resulted in

Scheme 1. Yields of the Ugi Products (1) and Cyclized 1,3-Oxazinan-2-one (2)




Table 1. Optimization of Reaction Conditions^a

entry	equiv of CDI	base	time (h)	<i>t</i> (°C)	yield (%) ^b
1	1		3	rt	76
2	1		3	50	83
3	2		3	rt	93
4	2		3	50	88
5	2	TEA	12	rt	61
6	2	DIPEA	12	rt	71
7	2	NaHCO ₃	12	rt	48
8	1.2		3	rt	85
9	1.5		3	rt	99


^aThe CDI conducted reaction was carried out in DCM with 1 M concentration. ^bIsolated yields.

^aIsolated yield of 1. ^bIsolated yield of 2.

moderate to good yields over two steps. First of all, amino substituents have obvious influences on synthetic conversion. Compounds synthesized by aromatic amines exhibited excellent overall yields, including phenox phenyl substituted **2e** despite the possible steric hindrance. On the contrary, aliphatic amine substitutions reduced the yield of the cyclization. For instance, compound **2c** with allyl substitution affords only 47% yield. In addition, changes in the isocyanide components were well-tolerated. Most of the isolated products have approximately 70% yield. It is noteworthy that the desired compound **2i** was obtained in high yield in the presence of a competitive amino group in the indole ring. Furthermore, aldehydes with methoxyl and halogen substituents on ortho- or meta-positions were evaluated in the scope as well. Surprisingly, most of the cyclization products with either mono- or multisubstituents on the salicylaldehydes gave extraordinary quantitative yields.

Encouraged by the initial results, we investigated the potential of the cyclization strategy based on Groebke-Blackburn-Bienaymé reactions (GBB reactions) which could afford secondary amines on imidazole heterobicyclic rings (Scheme 2).^{2–4} Equimolar amounts of aldehyde, amino amine,

Scheme 2. Yields of the GBB Products (3) and Cyclized Oxazepanones (4)




^aIsolated yield of 3. ^bIsolated yield of 4.

and isocyanide, as well as 0.08 equiv of HCl in dioxane, were combined in CH₃CN (1 M) in a microwave at 110 °C for 20 min. The corresponding imidazole-heterobicyclic product **3** was isolated by column chromatography with excellent yields (for example, **3c**, 97%). The identical cyclization approach as above was employed. Not surprisingly, the carbamate formation of the 7-membered 1,3-oxazepan-2-one appeared more difficult than the 6-membered 1,3-oxazinan-2-one. The overall yields of the cyclized GBB products are below 50%. A large amount of imidazole-1-carboxylate intermediates were observed even with a longer reaction time.

In light of the aforementioned results, we next explored the synthesis of thiocarbamate derivatives (Scheme 3). 1,1'-Thiocarbonyldiimidazole (TCDI), the sulfur analog of CDI, was employed as the thiocarbonyl donor. Accordingly, the reaction was conducted with 2 equiv of TCDI in room temperature for 12 h in DCM. To our delight, the overall cyclization exhibited good to excellent yields. Positively, enhanced conversion to the thiocarbamate compounds was observed in the Ugi products, compared with the carbamate formation. Furthermore, it is noteworthy that the thiocarbamate GBB product (**5c**, 84%) went better than carbamate GBB

Scheme 3. Substrate Scope of Cyclized 1,3-Oxazinane-2-thiones and 1,3-Oxazepane-2-thiones (5)




^aIsolated yield of cyclic thiocarbamate **5**.

(**4a**, 22%), effectively comparable with the Ugi product yields (**5a**, 77%; **5b**, 89%).

Next, we attempted to use the uniform approach with the sulfonyl donor 1,1'-sulfonyldiimidazole (SDI), for the synthesis of sulfamate derivatives (Scheme 4). However, under the

Scheme 4. Substrate Scope of Cyclized 1,2,3-Oxathiazinane-2,2-dioxides and 1,2,3-Oxathiazepane-2,2-dioxides (6)




^aIsolated yield of cyclic thiocarbamate **6**.

previous conditions, the reaction remained at the stage of the imidazole-1-sulfonyl intermediate instead of cyclization to the sulfamate product. In order to push the reaction to the desired cyclization, an excess amount of Cs₂CO₃ was added to the reaction solution. Under base catalysis, 6-membered and 7-membered cyclized sulfamate derivatives were then synthesized in 45% (**6a**) and 33% (**6b**) yields, respectively.

As an application of this methodology, we next investigated the scope of 5-membered carbamate cyclization and urea cyclization with CDI as the carbonyl donor (Scheme 5). The main innovation of 5-membered ring formation is the employment of various aldehydes. The glycolaldehyde dimer, providing a free hydroxyl group, was used in the azido-Ugi reaction. CDI afforded oxazolidin-2-one **8a** with 74% yield. Pyrrole-2-carboxaldehyde and 2-imidazolecarboxaldehyde, which provided secondary amines, were employed to the formation of heterobicyclic ureas with 99% (**8b**) and 60% (**8c**) yields, respectively. For better yields, a catalytic amount of DIPEA was added in the urea formation.

Scheme 5. Substrate Scope of 5-Membered CDI Cyclization of MCR Products (8)



^aIsolated yield of 7. ^bIsolated yield of 8.

Additionally, five oxazinanone derivatives (**2a**, **2b**, **2e**, **2k**, **2m**) and one oxazolidinone derivative (**8a**) have been confirmed by X-ray single-crystal analysis (Scheme 1, Scheme 5, and Supporting Information).

To exemplify the scaffolding induced property modulation, we compared 14 physicochemical properties of each 1000 compound virtual libraries^{30,31} of the cyclized and noncyclized structures (Figure 2 and Supporting Information). PCA of five




Figure 2. Normalized PC1 vs PC2 plot of cyclic and noncyclic molecules. Cyclic molecules (green) showed a different distribution against noncyclic molecules (pink).

nonredundant physicochemical properties included 3D descriptors allowing us to identify interesting differences between noncyclic and cyclic molecules. Topological polar surface area (TPSA) and logP, which are important values in medicinal chemistry, were identified as the most relevant descriptors (black arrows) to explain the variance among the cyclic and noncyclic molecules, indicating drug likeliness of all herein described cyclic scaffolds.

CONCLUSION

In summary, a MCR-based synthesis of 5-membered, 6-membered, and 7-membered cyclic carbamate derivatives with at least four substitutions has been developed with the purpose to modify physicochemical properties. Both the azido-Ugi reaction and the GBB reaction are instrumental in this approach, leading to potentially bioactive bis-heterocyclic or multiheterocyclic scaffold constructs. Furthermore, their thio and sulfur scaffolds are investigated along with the achieve-

ment of extraordinary scaffold diversity. The cheminformatics analysis clearly shows we are addressing a druglike chemical space. Our protocol, utilizing mild conditions and readily available building blocks, is of excellent maneuverability, scalability, and efficiency. It will add to a growing body in the development of material and organic synthesis, as well as medicinal chemistry.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acscombsci.0c00072>.

NMR spectra, crystal structure determinations, and chemical space exploration (PDF)

CIF 1 (CIF)

CIF 2 (CIF)

CIF 3 (CIF)

CIF 4 (CIF)

CIF 5 (CIF)

CIF 6 (CIF)

AUTHOR INFORMATION

Corresponding Author

Alexander Dömling – Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands; orcid.org/0000-0002-9923-8873; Email: a.s.s.domling@rug.nl; www.drugdesign.nl

Authors

Jingyao Li – Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands

Vincenzo Di Lorenzo – Department of Pharmacy, Università degli studi di Napoli Federico II, 80131 Napoli, Italy; Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands

Pravin Patil – Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands; orcid.org/0000-0002-0903-8174

Angel J. Ruiz-Moreno – Departamento de Farmacología, Unidad Periférica de Investigación en Biomedicina Traslacional, Facultad de Medicina y Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, C.P. 04510 Ciudad de México, México; Department of Drug Design, University of Groningen, 9713 AV Groningen, The Netherlands

Katarzyna Kurpiewska – Faculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland

Justyna Kalinowska-Tłuścik – Faculty of Chemistry, Jagiellonian University, 30-387 Krakow, Poland; orcid.org/0000-0001-7714-1651

Marco A. Velasco-Velázquez – Departamento de Farmacología, Unidad Periférica de Investigación en Biomedicina Traslacional, Facultad de Medicina y Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, C.P. 04510 Ciudad de México, México

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acscombsci.0c00072>

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research has been supported (A.D.) by the National Institute of Health (NIH) (2R01GM097082-05), the European Lead Factory (IMI) under grant agreement number 115489, and the Qatar National Research Foundation (NPRP6-065-3-012). Moreover, funding was received through ITN “Accelerated Early stage drug dIScovery” (AEGIS, grant agreement No. 675555), COFUND ALERT (grant agreement No. 665250), Hartstichting (ESCAPE-HF, 2018B012), and KWF Kankerbestrijding grant (grant agreement No. 10504). The authors thank Markella Konstantinidou (University of Groningen) for critical reading and careful revision of the manuscript and Marcel de Vries (University of Groningen) for his help in HRMS analysis. J.L. acknowledges the China Scholarship Council for financial support.

■ REFERENCES

- (1) Cioc, R. C.; Ruijter, E.; Orru, R. V. Multicomponent reactions: advanced tools for sustainable organic synthesis. *Green Chem.* **2014**, *16* (6), 2958–75.
- (2) Dömling, A. Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry. *Chem. Rev.* **2006**, *106* (1), 17–89.
- (3) Dömling, A.; Ugi, I. Multicomponent Reactions with Isocyanides. *Angew. Chem., Int. Ed.* **2000**, *39* (18), 3168–3210.
- (4) Boltjes, A.; Dömling, A. The Groebke-Blackburn-Bienaymé reaction. *Eur. J. Org. Chem.* **2019**, *2019*, 7007–7049.
- (5) Ugi, I.; Werner, B.; Dömling, A. The chemistry of isocyanides, their multicomponent reactions and their libraries. *Molecules* **2003**, *8* (1), 53–66.
- (6) Di, L.; Kerns, E. H. *Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization*; Academic Press: Dec 17, 2015; DOI: 10.1016/C2013-0-18378-X.
- (7) Hulme, C.; Gore, V. Multi-component Reactions: Emerging Chemistry in Drug Discovery “From Xylocain to Crixivan. *Curr. Med. Chem.* **2003**, *10* (1), 51–80.
- (8) Borthwick, A. D.; Liddle, J.; Davies, D. E.; Exall, A. M.; Hamlett, C.; Hickey, D. M.; Mason, A. M.; Smith, I. E.; Nerozzi, F.; Peace, S.; Pollard, D. Pyridyl-2, 5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. *J. Med. Chem.* **2012**, *55* (2), 783–796.
- (9) Ghosh, A. K.; Brindisi, M. Organic Carbamates in Drug Design and Medicinal Chemistry. *J. Med. Chem.* **2015**, *58* (7), 2895–2940.
- (10) Nicolaou, K. C.; Winssinger, N.; Pastor, J.; Murphy, F. Solid-Phase Synthesis of Macrocyclic Systems by a Cyclorelease Strategy: Application of the Stille Coupling to a Synthesis of (S)-Zearalenone. *Angew. Chem., Int. Ed.* **1998**, *37* (18), 2534–2537.
- (11) Evans, D. A.; Bartoli, J.; Shih, T. L. Enantioselective Aldol Condensations. 2. Erythro-Selective Chiral Aldol Condensations via Boron Enolates. *J. Am. Chem. Soc.* **1981**, *103* (8), 2127–2129.
- (12) Voit, B. I.; Lederer, A. Hyperbranched and Highly Branched Polymer Architectures-Synthetic Strategies and Major Characterization Aspects. *Chem. Rev.* **2009**, *109* (11), 5924–5973.
- (13) Kreye, O.; Mutlu, H.; Meier, M. A. R. Sustainable Routes to Polyurethane Precursors. *Green Chem.* **2013**, *15* (6), 1431–1455.
- (14) Aricò, F.; Bravo, S.; Crisma, M.; Tundo, P. 1,3-Oxazinan-2-Ones via Carbonate Chemistry: A Facile, High Yielding Synthetic Approach. *Pure Appl. Chem.* **2016**, *88* (3), 227–237.
- (15) Murdock, K. C. 2-Oxazolidinones from an N-Dealkylation Reaction of Phosgene with Dialkylaminoalknols. The Isolation and Reactivities of an N-Acyl Quaternary Ammonium Intermediate. *J. Org. Chem.* **1968**, *33* (4), 1367–1371.
- (16) Dao Thi, H.; Le Nhat Thuy, G.; Catak, S.; Van Speybroeck, V.; Van Nguyen, T.; D’Hooghe, M. Use of 3-Hydroxy-4-(Trifluoromethyl)Azetidin-2-Ones as Building Blocks for the Preparation of Trifluoromethyl-Containing Aminopropanes, 1,3-Oxazinan-2-Ones, Aziridines, and 1,4-Dioxan-2-Ones. *Synthesis* **2018**, *50* (07), 1439–1456.
- (17) Trifunović, S.; Dimitrijević, D.; Vasić, G.; Radulović, N.; Vukićević, M.; Heinemann, F. W.; Vukićević, R. D. New Simple Synthesis of N-Substituted 1,3-Oxazinan-2-Ones. *Synthesis* **2010**, *2010* (06), 943–946.
- (18) Kim, Y. J.; Varma, R. S. Microwave-Assisted Preparation of Cyclic Ureas from Diamines in the Presence of ZnO. *Tetrahedron Lett.* **2004**, *45* (39), 7205–7208.
- (19) Rice, G. T.; White, M. C. Allylic C-H Amination for the Preparation of Syn-1,3-Amino Alcohol Motifs. *J. Am. Chem. Soc.* **2009**, *131* (33), 11707–11711.
- (20) Nahra, F.; Liron, F.; Prestat, G.; Mealli, C.; Messaoudi, A.; Poli, G. Striking AcOH Acceleration in Direct Intramolecular Allylic Amination Reactions. *Chem. - Eur. J.* **2009**, *15* (42), 11078–11082.
- (21) Fujita, M.; Kitagawa, O.; Suzuki, T.; Taguchi, T. Regiocontrolled Iodoaminocyclization Reaction of an Ambident Nucleophile Mediated by Basic Metallic Reagent. *J. Org. Chem.* **1997**, *62* (21), 7330–7335.
- (22) Quinodoz, P.; Quelhas, A.; Wright, K.; Drouillat, B.; Marrot, J.; Couty, F. Iodocarbamation of N-Homopropargyl Carbamates: Mild and Stereoselective Entry to Functionalized Oxazinan-2-Ones. *Eur. J. Org. Chem.* **2017**, *2017*, 2621–2626.
- (23) Mangelinckx, S.; Nural, Y.; Dondas, H. A.; Denolf, B.; Sillanpää, R.; De Kimpe, N. Diastereoselective Synthesis of 6-Functionalized 4-Aryl-1,3-Oxazinan-2-Ones and Their Application in the Synthesis of 3-Aryl-1,3-Aminoalcohols and 6-Arylpiperidine-2,4-Diones. *Tetrahedron* **2010**, *66* (23), 4115–4124.
- (24) Ella-Menye, J. R.; Sharma, V.; Wang, G. New Synthesis of Chiral 1,3-Oxazinan-2-Ones from Carbohydrate Derivatives. *J. Org. Chem.* **2005**, *70* (2), 463–469.
- (25) Kayaki, Y.; Mori, N.; Ikariya, T. Palladium-Catalyzed Carboxylative Cyclization of α -Allenyl Amines in Dense Carbon Dioxide. *Tetrahedron Lett.* **2009**, *50* (47), 6491–6493.
- (26) Niemi, T.; Repo, T. Antibiotics from Carbon Dioxide: Sustainable Pathways to Pharmaceutically Relevant Cyclic Carbamates. *Eur. J. Org. Chem.* **2019**, *2019*, 1180–1188.
- (27) Staab, H. A. New Methods of Preparative Organic Chemistry IV. Syntheses Using Heterocyclic Amides (Azolides). *Angew. Chem., Int. Ed. Engl.* **1962**, *1* (7), 351–367.
- (28) Paul, R.; Anderson, G. W. N,N'-Carbonyldiimidazole, a New Peptide Forming Reagent. *J. Am. Chem. Soc.* **1960**, *82* (17), 4596–4600.
- (29) Larrivé-Aboussafy, C.; Jones, B. P.; Price, K. E.; Hardink, M. A.; McLaughlin, R. W.; Lillie, B. M.; Vaidyanathan, R. DBU catalysis of N, N'-carbonyldiimidazole-mediated amidations. *Org. Lett.* **2010**, *12* (2), 324–327.
- (30) Instant JChem was used for structure database management, search, and prediction; Instant JChem 19.4; 2019; ChemAxon. <http://www.chemaxon.com> (accessed 2020-06-03).
- (31) Reactor was used for enumeration and reaction modeling; JChem 19.4; 2019; ChemAxon. <http://www.chemaxon.com> (accessed 2020-06-03).